Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avid: Quick and early

There is keen interest in developing early diagnostics for degenerative diseases where early therapeutic intervention is likely to provide the greatest benefit but diagnosis is still largely dependent on an assessment of symptoms. Avid Radiopharmaceuticals Inc. is developing a pipeline of targeted radioactive small molecules that it hopes may one day allow for routine early screening for Alzheimer's disease, Parkinson's disease/dementia with Lewy bodies (DLB) and diabetes.

Avid (Philadelphia, Penn.) has

Read the full 701 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers